ID: ALA25620

Max Phase: Preclinical

Molecular Formula: C28H18N4O3

Molecular Weight: 458.48

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cn1cncc1C(O)(C#Cc1ccc(C#N)cc1-c1ccc2c(c1)OCO2)c1ccc(C#N)cc1

Standard InChI:  InChI=1S/C28H18N4O3/c1-32-17-31-16-27(32)28(33,23-7-3-19(14-29)4-8-23)11-10-21-5-2-20(15-30)12-24(21)22-6-9-25-26(13-22)35-18-34-25/h2-9,12-13,16-17,33H,18H2,1H3

Standard InChI Key:  RXGGZGACWDLIGX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 458.48

Molecular Weight (Monoisotopic): 458.1379

AlogP: 3.85

#Rotatable Bonds: 3

Polar Surface Area: 104.09

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.19

CX Basic pKa: 5.87

CX LogP: 3.98

CX LogD: 3.97

Aromatic Rings: 4

Heavy Atoms: 35

QED Weighted: 0.47

Np Likeness Score: -0.60

References

1. Lin NH, Wang L, Cohen J, Gu WZ, Frost D, Zhang H, Rosenberg S, Sham H..  (2003)  Synthesis and biological evaluation of 4-[3-biphenyl-2-yl-1-hydroxy-1-(3-methyl-3H-imidazol-4-yl)-prop-2-ynyl]-1-yl-benzonitrile as novel farnesyltransferase inhibitor.,  13  (7): [PMID:12657267] [10.1016/s0960-894x(03)00122-7]

Source

Source(1):

• Scientific Literature